{
    "nct_id": "NCT03180684",
    "official_title": "A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRAâ„¢ 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Vulva",
    "inclusion_criteria": "* Women aged 18 and above;\n* Have high grade squamous intraepithelial lesion (HSIL) of the vulva (VIN2 or VIN3) caused by infection with HPV types 16 and/or 18 confirmed at screening visit;\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Biopsy-proven differentiated VIN;\n* Any previous treatment for vulvar HSIL within 4 weeks prior to screening;\n* Allergy to imiquimod 5% cream or to an inactive ingredient in imiquimod 5% cream;\n* Pregnant, breastfeeding or considering becoming pregnant within 6 months following the last dose of investigational product;\n* Immunosuppression as a result of underlying illness or treatment;\n* Significant acute or chronic medical illness.",
    "miscellaneous_criteria": ""
}